Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10029


The purpose of this study is to see if changing from one pain medication like morphine or oxycodone to another pain medication, oxymorphone (OPANA®), will be helpful to patients. This study will examine if the switching from one pain medication to another can be done over a 24 hour period. Oxymorhone, the drug being studied, is an FDA approved drug for treatment of severe pain.


Inclusion Criteria: - Age of 18 to no upper limit - Chronic pain of nociceptive, neuropathic, or mixed origin - Patients with chronic non cancer pain - Ongoing chronic opioid treatment with either oral morphine or oxycodone (long term - more than 3 months of at least a total daily opioid dose of 60 mg morphine or of 30 mg oxycodone) - Pain of moderate intensity (>4, on the numerical scale 0-10) despite ongoing opioid therapy> - Non-pregnant, non-lactating women - Sufficient language skills to communicate with research staff Exclusion Criteria:Non-ambulatory patients - Clinically significant respiratory, renal, hepatic, or cardiac disease. - Documented diagnosis of sleep apnea (the study physician may exclude patients who present with clinical features and complaints suggestive of a diagnosis of probable sleep apnea) - History of illicit drug or alcohol dependence or abuse, abnormal drug taking / seeking behaviors - Severe depression (> 26 on the BDI) - Patients who exhibit a score on the Mini Mental Status Exam (MMSE) of 26 or less. (The range of scores for mild dementia is 21-26 on the MMSE). - Workman compensation, current or pending medical-legal litigation - Hypersensitivity to study medication (oxymorphone)

Study is Available At:

Original ID:

GCO# 07-0464



Secondary ID:

Study Acronym:

Brief Title:

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

Official Title:

A Pilot Study of Rapid Opioid Rotation and Titration of Oxymorphone

Overall Status:


Study Phase:




Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Mount Sinai School of Medicine

Oversight Authority:

United States: Institutional Review Board

Reasons Why Stopped:

Study Type:


Study Design:

Intervention Model: Single Group Assignment, Mask

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Marco Pappagallo, MD
Principal Investigator
Mount Sinai School of Medcine

Study Dates

Start Date:November 2007
Completion Date:August 2008
Completion Type:Actual
Primary Completion Date:August 2008
Primary Completion Type:Actual
Verification Date:July 2011
Last Changed Date:March 7, 2012
First Received Date:December 19, 2007

Study Outcomes

Outcome Type:Primary Outcome
Measure:Brief Pain Inventory
Time Frame:Assessed daily for 10 days prior to IV PCA treatment, and assessed daily for 2 weeks after IV PCA tr
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Patient Global Impression of Change
Time Frame:end of study
Safety Issues:False

Study Interventions

Intervention Type:Drug
Name:oxymorphone IV
Description:IV PO
Arm Name:1
Other Name:Oxymorphone PO

Study Arms

Study Arm Type:Experimental
Arm Name:1

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Mount Sinai School of Medicine
Agency Class:Industry
Agency Type:Collaborator
Agency Name:Endo Pharmaceuticals

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.